<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://tickerreport.com/feed/</forum>
<forum_title>Ticker Report</forum_title>
<discussion_title>Brokerages Set Strongbridge Biopharma (NASDAQ:SBBP) Price Target at $11.94</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.tickerreport.com/banking-finance/2084379/brokerages-set-strongbridge-biopharma-nasdaqsbbp-price-target-at-11-94/</topic_url>
<topic_text>
Tweet 
Strongbridge Biopharma (NASDAQ:SBBP) has received a consensus rating of “Buy” from the six analysts that are presently covering the company. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $11.94. 
SBBP has been the topic of several analyst reports. Zacks Investment Research raised Strongbridge Biopharma from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research note on Wednesday, July 20th. HC Wainwright reissued a “buy” rating on shares of Strongbridge Biopharma in a research note on Wednesday, June 22nd. 
Shares of Strongbridge Biopharma ( NASDAQ:SBBP ) opened at 4.61 on Friday. Strongbridge Biopharma has a one year low of $3.30 and a one year high of $14.30. The firm’s market capitalization is $97.76 million. The stock’s 50 day moving average price is $4.23 and its 200 day moving average price is $4.45. 
Strongbridge Biopharma plc, formerly Cortendo plc, is a development-stage biopharmaceutical company. The Company is engaged in advancing its product candidates through clinical development. The Company is focused on the development, in-licensing, acquisition and eventual commercialization of several complementary products and product candidates within franchises that target rare diseases.   Strongbridge Biopharma   Strongbridge Biopharma  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.tickerreport.com/banking-finance/2084379/brokerages-set-strongbridge-biopharma-nasdaqsbbp-price-target-at-11-94/</post_url>
<post_date>20160822</post_date>
<post_time>0750</post_time>
<username>Ethan Ryder</username>
<post>
Tweet 
Strongbridge Biopharma (NASDAQ:SBBP) has received a consensus rating of “Buy” from the six analysts that are presently covering the company. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $11.94. 
SBBP has been the topic of several analyst reports. Zacks Investment Research raised Strongbridge Biopharma from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research note on Wednesday, July 20th. HC Wainwright reissued a “buy” rating on shares of Strongbridge Biopharma in a research note on Wednesday, June 22nd. 
Shares of Strongbridge Biopharma ( NASDAQ:SBBP ) opened at 4.61 on Friday. Strongbridge Biopharma has a one year low of $3.30 and a one year high of $14.30. The firm’s market capitalization is $97.76 million. The stock’s 50 day moving average price is $4.23 and its 200 day moving average price is $4.45. 
Strongbridge Biopharma plc, formerly Cortendo plc, is a development-stage biopharmaceutical company. The Company is engaged in advancing its product candidates through clinical development. The Company is focused on the development, in-licensing, acquisition and eventual commercialization of several complementary products and product candidates within franchises that target rare diseases.   Strongbridge Biopharma   Strongbridge Biopharma  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.tickerreport.com/logos/strongbridge-biopharma-plc-logo.png</main_image>
</document>
